HBIO
Harvard Bioscience, Inc.0.7000
-0.0032-0.46%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Key Stats
Market Cap
31.21MP/E (TTM)
-Basic EPS (TTM)
-1.21Dividend Yield
0%Recent Filings
8-K
FY25 results, FY26 guidance
Harvard Bioscience released its March 2026 investor presentation under Regulation FD, highlighting FY25 results of $87M revenue, 58% adjusted gross margin, and $8M adjusted EBITDA amid a 2025 goodwill impairment. New leadership, debt refinancing to 2029 saving $3M annually, and Holliston plant closure promise $3M EBITDA lift in 2027. Guides 2-4% revenue growth, 58-60% margins, 6-10% EBITDA growth in FY26. Plant closure unlocks leverage.
10-K
FY2025 10-K excerpt
Harvard Bioscience's 10-K for FY2025 ended December 31, 2025 lacks financial statements, quarterly breakdowns, or MD&A results, so topline revenue, profitability, and Q4 metrics remain undisclosed. No y/y annual deltas, q/q trends, segment performance, EPS figures, or liquidity details appear in the provided filing excerpt. Free cash flow not disclosed in the 10-K. Capital allocation actions undisclosed. Q4 momentum impossible to assess. No annual guidance provided. Supply chain disruptions pose a key risk from Risk Factors.
8-K
Q4 revenues $23.7M, margin up
Harvard Bioscience reported Q4 2025 revenues of $23.7M, down slightly from $24.6M, yet gross margin rose to 59.7% on cost cuts and better mix. Full-year sales fell to $86.6M amid market woes and $48M goodwill hit, but adjusted EBITDA climbed to $8.1M while cash hit $8.6M. Mark Frost now permanent CFO. 2026 guides 2-4% revenue growth via new translational science products.
8-K
Execs get amended deals
Harvard Bioscience amended CEO John Duke's employment agreement on March 6, 2026, setting $515,000 base salary through July 2027 with 80% bonus potential and 75,000 post-split RSUs targeted for 2026; simultaneously promoted Mark Frost from interim to permanent CFO with $375,000 salary through April 2027, 60% bonus upside, and 30,000 RSUs. Both pacts tie $100,000 Duke bonus to credit facility refinancing. Leadership locked in amid restructuring.
8-K
1-for-10 reverse split approved
Harvard Bioscience stockholders overwhelmingly approved a reverse stock split on March 6, 2026, with the board selecting a 1-for-10 ratio effective 4:30 p.m. ET March 13. This slashes outstanding shares from ~44.7M to ~4.5M, aiming to boost the per-share price for Nasdaq minimum bid compliance. Trading resumes split-adjusted March 16. No fractional shares; cash paid instead.
IPO
Employees
Sector
Industry
BDX
Becton, Dickinson and Company
196.39-3.70
BIO
Bio-Rad Laboratories, Inc.
302.02-5.90
BLFS
BioLife Solutions, Inc.
24.61-0.04
BRKR
Bruker Corporation
44.96-0.71
DHR
Danaher Corporation
224.70-3.83
HRGN
Harvard Apparatus Regenerative
2.00+0.21
PLSE
Pulse Biosciences, Inc
14.23+0.10
RSCF
Reflect Scientific, Inc.
0.05+0.00
SOAGY
Sartorius AG
56.43-0.16
TMO
Thermo Fisher Scientific Inc
570.16-5.75